Drugs / S-trans,trans-Farnesylthiosalicylic Acid
S-trans,trans-Farnesylthiosalicylic Acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00867230 | May 2006 → Feb 2009 | leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-Trans, Trans-Farnesylthiosalicylic Acid | “S-trans,trans-Farnesylthiosalicylic Acid (FTS, salirasib) inhibits Ras-dependent cell growth by dislodging all isoforms of Ras, including mutant Ras, from the plasma membrane.” PMID 22547163 ↗ May 2012 |
| Known as | FTS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00867230 ↗ |
| Known as | salirasib | “S-trans,trans-Farnesylthiosalicylic Acid (FTS, salirasib) inhibits Ras-dependent cell growth by dislodging all isoforms of Ras, including mutant Ras, from the plasma membrane.” PMID 22547163 ↗ May 2012 |
| Action | Inhibit | “S-trans,trans-Farnesylthiosalicylic Acid (FTS, salirasib) inhibits Ras-dependent cell growth by dislodging all isoforms of Ras, including mutant Ras, from the plasma membrane.” PMID 22547163 ↗ May 2012 |
| Route | Oral | “after daily oral administration” NCT00867230 ↗ |